Discovery of Pyrrolidine-2,3-diones as Novel Inhibitors of P. aeruginosa PBP3
Authors:
- Arancha López-PérezALArancha López-Pérez
- Stefan FreischemSFStefan Freischem
- Immanuel GrimmIGImmanuel Grimm
- Oliver WeiergräberOWOliver Weiergräber
- Andrew J. DingleyADAndrew J. Dingley
- María Pascual López-AlbercaMLMaría Pascual López-Alberca
- Herbert WaldmannHWHerbert Waldmann
- Waldemar VollmerWVWaldemar Vollmer
- Kamal KumarKKKamal Kumar
- Cuong VuongCVCuong Vuong
Open Access
- 4 May 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (5) , 529
Abstract
The alarming threat of the spread of multidrug resistant bacteria currently leaves clinicians with very limited options to combat infections, especially those from Gram-negative bacteria. Hence, innovative strategies to deliver the next generation of antibacterials are urgently needed. Penicillin binding proteins (PBPs) are proven targets inhibited by β-lactam antibiotics. To discover novel, non-β-lactam inhibitors against PBP3 of Pseudomonas aeruginosa, we optimised a fluorescence assay based on a well-known thioester artificial substrate and performed a target screening using a focused protease-targeted library of 2455 compounds, which led to the identification of pyrrolidine-2,3-dione as a potential scaffold to inhibit the PBP3 target. Further chemical optimisation using a one-pot three-component reaction protocol delivered compounds with excellent target inhibition, initial antibacterial activities against P. aeruginosa and no apparent cytotoxicity. Our investigation revealed the key structural features; for instance, 3-hydroxyl group (R2) and a heteroaryl group (R1) appended to the N-pyrroldine-2,3-dione via methylene linker required for target inhibition. Overall, the discovery of the pyrrolidine-2,3-dione class of inhibitors of PBP3 brings opportunities to target multidrug-resistant bacterial strains and calls for further optimisation to improve antibacterial activity against P. aeruginosa.Keywords
Funding Information
- Horizon 2020 (No 721484)
- Anti-Infective Cures GmbH (ND)
This publication has 50 references indexed in Scilit:
- High-Throughput Screening for Novel Inhibitors of Neisseria gonorrhoeae Penicillin-Binding Protein 2PLOS ONE, 2012
- An Optimised Small‐Molecule Stabiliser of the 14‐3‐3–PMA2 Protein–Protein InteractionChemistry – A European Journal, 2012
- Unexpected Tricovalent Binding Mode of Boronic Acids within the Active Site of a Penicillin-Binding ProteinJournal of the American Chemical Society, 2011
- New Noncovalent Inhibitors of Penicillin-Binding Proteins from Penicillin-Resistant BacteriaPLOS ONE, 2011
- Mycobacterium Tuberculosis Infection and Inflammation: what is Beneficial for the Host and for the Bacterium?Frontiers in Microbiology, 2011
- Pseudomonas aeruginosa Genomic Structure and DiversityFrontiers in Microbiology, 2011
- MexCD-OprJ Multidrug Efflux System of Pseudomonas aeruginosa : Involvement in Chlorhexidine Resistance and Induction by Membrane-Damaging Agents Dependent upon the AlgU Stress Response Sigma FactorAntimicrobial Agents and Chemotherapy, 2008
- The penicillin-binding proteins: structure and role in peptidoglycan biosynthesisFEMS Microbiology Reviews, 2008
- Screening in a spirit haunted worldDrug Discovery Today, 2006
- A detergent-based assay for the detection of promiscuous inhibitorsNature Protocols, 2006